2021-08-26
Laekna Therapeutics receives IND approvals in China and US for phase Ib/III global multi-center clinical study of afuresertib in combination with fulvestrant for patients with hr+/her2- breast cancer
Laekna Therapeutics receives IND approvals in China and US for phase Ib/III global multi-center clinical study of afuresertib in combination with fulvestrant for patients with hr+/her2- breast cancer
More
More